title: A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
authors.affiliation: O.U.C. Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto (IOV - IRCCS ) Padua, Italy. fzustovich@ulss16.padova.it
authors.forename: F
authors.initials: F
authors.lastname: Zustovich
authors.forename: G
authors.initials: G
authors.lastname: Cartei
authors.forename: M
authors.initials: M
authors.lastname: Dal Bianco
authors.forename: L
authors.initials: L
authors.lastname: De Zorzi
authors.forename: R
authors.initials: R
authors.lastname: Ceravolo
authors.forename: S
authors.initials: S
authors.lastname: Zovato
authors.forename: F
authors.initials: F
authors.lastname: Salmaso
authors.forename: S
authors.initials: S
authors.lastname: Binato
authors.forename: G
authors.initials: G
authors.lastname: Artioli
authors.forename: S
authors.initials: S
authors.lastname: Cingarlini
authors.forename: D
authors.initials: D
authors.lastname: Pastorelli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019772:Topotecan / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D003841:Deoxycytidine; D019772:Topotecan; D000093542:Gemcitabine